Yazaki, Shu
Salgado, Roberto http://orcid.org/0000-0002-1110-3801
Shimoi, Tatsunori http://orcid.org/0000-0002-3603-8575
Yoshida, Masayuki
Shiino, Sho
Kaneda, Tomoya
Kojima, Yuki
Sumiyoshi-Okuma, Hitomi http://orcid.org/0000-0001-9639-7361
Nishikawa, Tadaaki
Sudo, Kazuki
Noguchi, Emi http://orcid.org/0000-0003-0326-7555
Murata, Takeshi
Takayama, Shin
Suto, Akihiko
Ohe, Yuichiro
Yonemori, Kan
Article History
Received: 19 June 2022
Revised: 8 November 2022
Accepted: 15 November 2022
First Online: 15 December 2022
Competing interests
: RS reports non-financial support from Merck and Bristol Myers Squibb (BMS), research support from Merck, Puma Biotechnology and Roche, and personal fees from Roche, BMS and Exact Sciences for advisory boards, outside the submitted work. MY reports no competing non-financial interests but personal fees from Chugai, outside the submitted work; TN reports no competing non-financial interests, but personal fees from Takeda Pharmaceutical Company, Eisai, AstraZeneca, Taiho, MSD, outside the submitted work; YO reports no competing non-financial interests, but grants and personal fees from AstraZeneca, Amgen, BMS, Chugai, Eli Lilly, Janssen, Kyorin, Nippon Kayaku, Novartis, Ono Pharmaceutical Company, MSD, Pfizer, Taiho, and Takeda Pharmaceutical Company, personal fees from Boehringer Ingelheim and Celtrion, and grants from Kissei, outside the submitted work; KY reports no competing non-financial interests, but personal fees from Pfizer, AstraZeneca, Eisai, Takeda Pharmaceutical Company, Chugai, Ono Pharmaceutical Company, Novartis, Daiichi Sankyo, outside the submitted work. All remaining authors declare no competing financial or non-financial interest.
: This study was approved by the Institutional Review Board of the National Cancer Center (No. 2014-092). The need for informed consent was waived because of the retrospective nature of the study.
: Not applicable.